ArticleJournal of managed care & specialty pharmacy2023

The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations.

Luis Hernandez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.